Wall Street Zen Upgrades Lyra Therapeutics (NASDAQ:LYRA) to Sell
Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Friday. Separately, HC Wainwright restated a “neutral” rating and set a $100.00 price objective on shares of Lyra Therapeutics in a research report on Friday, March 14th. […]
Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Friday. Separately, HC Wainwright restated a “neutral” rating and set a $100.00 price objective on shares of Lyra Therapeutics in a research report on Friday, March 14th. […]
